| Identification | Back Directory | [Name]
JAK2/FLT3-IN-1 | [CAS]
2387765-27-5 | [Synonyms]
Flonoltinib
JAK2/FLT3-IN-1
JAK2/FLT3 IN 1,JAK-2/FLT3-IN-1,JAK2/FLT3IN1
Ethanol, 2-[[1-[2-fluoro-4-[[5-methyl-4-[1-(1-methylethyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]phenyl]-4-piperidinyl]methylamino]- | [Molecular Formula]
C25H34FN7O | [MDL Number]
MFCD32263440 | [MOL File]
2387765-27-5.mol | [Molecular Weight]
467.59 |
| Chemical Properties | Back Directory | [Boiling point ]
660.2±65.0 °C(Predicted) | [density ]
1.26±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
14.74±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Flonoltinib is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib has anti-cancer activity[1]. | [in vivo]
Flonoltinib (30 and 60 mg/kg/day; p.o.; for 14 days) exhibits significant antitumor effects[1]. | Animal Model: | NOD/SCID mouse models[1] | | Dosage: | 30 and 60 mg/kg | | Administration: | Oral administration; daily; for 14 days | | Result: | Exhibited significant antitumor effects.
The tumor growth inhibitory rates (TGI) were respective 58% and 93% in the MV4-11-bearing mice model.
|
| [IC 50]
JAK2: 0.7 nM (IC50); FLT3: 4 nM (IC50); JAK1: 26 nM (IC50); JAK3: 39 nM (IC50) | [References]
[1] Yang T, et al. Discovery of Potent and Orally Effective Dual JAK2/FLT3 Inhibitors for the Treatment of AcuteMyelogenous Leukemia and Myeloproliferative Neoplasms. J Med Chem. 2019 Oct 31. DOI:10.1021/acs.jmedchem.9b01348 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|